Published in Br J Radiol on October 01, 1982
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) (2001) 1.35
A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol) (1996) 1.31
Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol (2011) 1.13
A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell density. Br J Radiol (2006) 1.12
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer (1989) 1.12
The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol (2003) 1.11
Mathematical models of tumour and normal tissue response. Acta Oncol (1999) 1.07
The assessment of the body distribution of yttrium-90 ferric hydroxide during radiation synovectomy. Br J Radiol (1976) 1.07
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer (1988) 1.06
Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br J Radiol (2006) 1.02
A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol (2001) 0.91
The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol (2005) 0.89
Active minimisation of radiation scatter during breast radiotherapy: management implications for young patients with good-prognosis primary neoplasms. Radiother Oncol (1996) 0.87
Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. Phys Med Biol (2010) 0.87
Comments on Inadequacy of iridium implant as sole radiation treatment for operable breast cancer, Fentiman et al., Eur J Cancer 1996, 32A, pp. 608-611. Eur J Cancer (1997) 0.87
The potential impact of relative biological effectiveness uncertainty on charged particle treatment prescriptions. Br J Radiol (2011) 0.87
Cell loss factors and the linear-quadratic model. Radiother Oncol (1995) 0.86
Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.85
Use of second antibody in radioimmunotherapy. NCI Monogr (1987) 0.84
High dose rate brachytherapy practice for the treatment of gynaecological cancers in the UK. Br J Radiol (1999) 0.82
Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) (1997) 0.82
Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol (2008) 0.81
Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. Med Phys (1983) 0.81
Determination of the optimum dose per fraction in fractionated radiotherapy when there is delayed onset of tumour repopulation during treatment. Br J Radiol (2004) 0.80
The reduction of tumour control with increasing overall time: mathematical considerations. Br J Radiol (1996) 0.80
Particle radiotherapy in the UK. Clin Oncol (R Coll Radiol) (2007) 0.80
Estimation of optimum dose per fraction for high LET radiations: implications for proton radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.80
Results of a questionnaire regarding the practice of radiotherapy for carcinoma of the cervix in the UK. Br J Radiol (1994) 0.80
Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy. Phys Med Biol (2006) 0.80
Derivation of the optimum dose per fraction from the linear quadratic model. Br J Radiol (1995) 0.79
Radiobiological modeling and clinical trials. Int J Radiat Oncol Biol Phys (2000) 0.79
Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer. Br J Cancer (1998) 0.78
Radiobiological compensation of treatment errors in radiotherapy. Br J Radiol (2008) 0.78
Repair kinetic considerations in particle beam radiotherapy. Br J Radiol (2011) 0.78
A graphical method to simplify the application of the linear-quadratic dose-effect equation to fractionated radiotherapy. Br J Radiol (1986) 0.78
Inclusion of molecular biotherapies with radical radiotherapy: modeling of combined modality treatment schedules. Int J Radiat Oncol Biol Phys (1999) 0.78
The potential of ytterbium 169 in brachytherapy: a brief physical and radiobiological assessment. Br J Radiol (1992) 0.78
Radiobiologically based assessments of the net costs of fractionated focal radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.77
Theoretical implications of incorporating relative biological effectiveness into radiobiological equivalence relationships. Br J Radiol (2013) 0.75
Comment on "Analysis of factors affecting the therapeutic gain in high dose rate gynecological implants relative to low dose rate implants" [Med. Phys. 23, 419-425 (1996)]. Med Phys (1996) 0.75
Conventional wisdom and activities of the middle range. Br J Radiol (2005) 0.75
Regarding Giap and Massullo, IJROBP 1999;45:1355-1358. Int J Radiat Oncol Biol Phys (2000) 0.75
The BJR and progress in radiobiological modelling. Br J Radiol (2010) 0.75
Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes". Br J Radiol (2011) 0.75
Accelerated fractionation (AF) in head and neck cancers. Radiother Oncol (1998) 0.75
Proceedings: The relationship between iso-effect dose and overall irradiation time in an organized tissue. Br J Radiol (1975) 0.75
Radial dose function (RDF) Int J Radiat Oncol Biol Phys (1989) 0.75
A mathematical model of intraluminal and intracavitary brachytherapy. Br J Radiol (1994) 0.75
Calculation by computer of dose distributions for superficial gold-198 implants and the derivation of optimized distribution rules. Br J Radiol (1976) 0.75
BED-time charts and their application to the problems of interruptions in external beam radiotherapy treatments. Int J Radiat Oncol Biol Phys (1999) 0.75
A Fortran program for fast and compact processing of clinical radiotherapy data. Comput Biol Med (1984) 0.75
A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90. Phys Med Biol (2006) 0.75
Radiobiology of changes in dose-rate. Sonderb Strahlenther Onkol (1988) 0.75
Implications of overall time in radiotherapy. Clin Oncol (R Coll Radiol) (1993) 0.75
The incorporation of specific tissue/nuclide attenuation data into the Anderson method for producing brachytherapy volume-dose histograms. Phys Med Biol (1990) 0.75
Estimation of tumour hypoxic fraction from clinical data sets compatible with accelerated repopulation. Acta Oncol (1998) 0.75
Quality control of linear accelerator x-ray performance using semiconductor probes. Radiology (1985) 0.75
Plasma TGFbeta1 during pelvic radiotherapy for gynaecological malignancy. Acta Oncol (2006) 0.75
Case report: low dose rate and high dose rate intracavitary brachytherapy in a patient with carcinoma of the cervix. Br J Radiol (1996) 0.75
Revisions to radial dose function data for 125I and 131Cs. Med Phys (1987) 0.75
Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. Br J Radiol (2007) 0.75
Implementation of the Philips treatment planning system for use in radiation teletherapy. Br J Radiol (1978) 0.75